SCHEMBL20028606

SCHEMBL20028606

Cn1cc(C(=O)NC(Cc2ccccc2)C(O)C(N)=O)c(-c2ccccc2F)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PYGL P06737 3/20 0.43
▸ DCAF1 Q9Y4B6 2/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ POLB P06746 1/20 0.39
▸ CNR1 P21554 4/20 0.38
▸ CNR2 P34972 4/20 0.38
▸ CTSA P10619 1/20 0.38
▸ CTSL P07711 1/20 0.37
▸ PSMB5 P28074 1/20 0.36
▸ MAPT P10636 1/20 0.36
▸ CCR1 P32246 1/20 0.36
▸ TACR3 P29371 1/20 0.36
▸ MAPK1 P28482 2/20 0.36
▸ ROCK2 O75116 1/20 0.36
▸ RPS6KA5 O75582 1/20 0.36
▸ RPS6KA4 O75676 1/20 0.36
▸ PRKACA P17612 1/20 0.36
▸ GSK3B P49841 1/20 0.36
▸ PRKX P51817 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22885979 0.90 PYGL (0.46) PYGLDCAF1MEN1KMT2APOLB
SCHEMBL20027914 0.86 DCAF1 (0.48) PYGLDCAF1MEN1KMT2A
SCHEMBL21854245 0.84 CAPN1 (0.51) DCAF1
SCHEMBL20027555 0.84 CAPN1 (0.51) DCAF1
SCHEMBL20028717 0.83 DCAF1 (0.50) PYGLDCAF1KMT2ACNR1CNR2
SCHEMBL20028599 0.82 ROCK2 (0.53) DCAF1MEN1KMT2APOLBCTSA
SCHEMBL22885966 0.82 CTSV (0.48) PYGLDCAF1CNR1CNR2CTSL
SCHEMBL22885920 0.82 PYGL (0.40) PYGLDCAF1CNR1CNR2CCR1
SCHEMBL22886842 0.82 DCAF1 (0.39) PYGLDCAF1CNR1CNR2CTSL
SCHEMBL22886578 0.82 IDO1 (0.44) PYGLDCAF1CNR1CNR2CCR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2018064119-A1 CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF BLADE THERAPEUTICS, INC. (US) 2018-04-05 — — WO disclosed
Send feedback